Does Oral NMN Survive the Gut? In Human Trials, Blood NAD+ Rose

‘Doesn’t my body make enough NAD+ already?’

Your body does make NAD+ on its own. A precursor adds to it: in a randomized, placebo-controlled 14-day trial of 65 healthy adults, NR and NMN both raised circulatory NAD+, while nicotinamide did not (Christen 2026). In older adults, 250 mg of NMN a day for 12 weeks raised blood NAD+ over placebo (Morifuji 2024).

‘Oral NMN gets destroyed in the gut’

This is a common doubt, and the trials do not support it as a reason NMN can’t work. In the 14-day trial of 65 healthy adults, daily NMN raised circulatory NAD+. Using human gut bacteria in the lab, the authors found NR and NMN are turned into nicotinic acid, and they propose that this gut-made form raises NAD+ through the Preiss-Handler pathway (Christen 2026). So, on the authors’ model, the marker can rise without NMN being absorbed intact. The study did not show whether any intact NMN reaches the blood, and that question is open.

‘It’s all mouse data’

It is not. A 60-adult, 12-week trial raised blood NAD+ in older adults (Morifuji 2024). A trial in healthy older men taking 250 mg a day for 6 or 12 weeks did the same (Igarashi 2022). A 6-week trial of 48 recreational runners found that 600 and 1,200 mg a day raised measures of aerobic capacity more than placebo while they trained (Liao 2021). A 65-adult, 14-day trial compared NR, NMN and nicotinamide in the same study (Christen 2026). For NR, a 2 × 6-week crossover trial raised NAD+ in healthy middle-aged and older adults (Martens 2018). A 2025 meta-analysis of 12 studies and 513 adults found NMN raised blood NAD+ overall (Zhang 2025).

‘The trials are small and short’

Fair. The trials above enrolled a few dozen people each and ran for two to twelve weeks (Christen 2026; Liao 2021; Morifuji 2024). Morifuji and Liao were double-blind and placebo-controlled; Christen was placebo-controlled but open-label. The 2025 meta-analysis rated risk of bias as “some concerns” in seven of its 12 studies and high in the other five (Zhang 2025). A 2026 review of 15 trials, lasting 14 days to 24 weeks, called for larger and longer trials (Yang 2026).

‘Does it raise the right thing, or just a marker?’

Blood NAD+ is what a precursor is meant to raise, and the 2025 meta-analysis found NMN did so across 12 studies and 513 adults (Zhang 2025). Some trials also measured function: older adults on 250 mg a day had shorter 4-meter walking times and better sleep-quality scores than placebo after 12 weeks, though the main stepping test showed no difference (Morifuji 2024), and runners on 600 or 1,200 mg a day improved aerobic-capacity measures, though not VO2max itself (Liao 2021).

Not every outcome moved. The same meta-analysis found no significant difference on most of the other outcomes it pooled (Zhang 2025), and a 2025 review of NMN and NR trials in adults with mean ages of 60.9 to 83 found no significant effect of NMN on handgrip strength, gait speed or muscle mass (Prokopidis 2025).

‘How much did the trials use?’

The older-adult trials gave 250 mg a day (Morifuji 2024; Igarashi 2022), the runner trial 300, 600 or 1,200 mg a day (Liao 2021), and the trials in a 2026 review ranged from 250 to 2,000 mg a day (Yang 2026). At 250 mg per capsule, one capsule matches the 250 mg trials, and a two-capsule serving gives 500 mg. Cost per dose depends on pack size and changes often, so check the price table rather than a sticker price. Our code HEALTHSPAN takes 10% off.